Eligen® Technology Mechanism of Action

Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity. After oral ingestion, the drug-carrier combination comes in contact with stomach/intestinal membrane. Delivery agent chaperones compound through the gastrointestinal (GI) membrane, with weak intermolecular forces allowing for separation. Download this free whitepaper, complete with an insightful diagram, to find out more.

More About This Company

Development Update

Novo Nordisk announced the European Commission (EC) has granted marketing authorisation for Rybelsus®, (oral semaglutide),...